Supreme Court Declines to Hear ANDA Jurisdiction Case

Drug Industry Daily
A A
The Supreme Court has rejected Mylan’s challenge to a Federal Circuit decision that generic-drugmakers can face patent suits anywhere they may make sales in the future.

To View This Article:

Login

Subscribe To Drug Industry Daily